AKT1 and acute lymphoblastic leukemia: If not attenuated, constitutive activation of the AKT signaling pathway negatively influences the response to therapeutic treatments, correlates with drug resistance, and is associated with a poor prognosis for ALL patients [22,23,24,25,26].